ReviewCurrent allergy and asthma reports2026
Sublingual Immunotherapy for Food Allergy: Updates in Safety, Efficacy, and Future Considerations.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewWith the continued increase in the prevalence of food allergy and its significant associated medical and financial burden, there is a need for safe and effective treatment options for patients. The goal of this review is to summarize published data on the safety and efficacy of peanut sublingual immunotherapy (SLIT) as a potential treatment option for children with food allergy. RECENT
findingsPeanut SLIT has demonstrated clinically significant desensitization across 2 cohorts of children ages 1-11 years. In a study focused on 1-4-year-old peanut-allergic toddlers, even greater levels of desensitization as well as the potential for 3-month remission has been demonstrated. Small studies have also demonstrated potential efficacy with SLIT for other foods such as milk, hazelnut, and peach. Evidence to date supports SLIT as effective and safe and a potential future treatment option for children with food allergy.
Indexed as
Identifiers
41484661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.